Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity DOI Creative Commons
Artur Galushkin, Illana Gozes

Advanced Drug Delivery Reviews, Год журнала: 2025, Номер 220, С. 115573 - 115573

Опубликована: Апрель 4, 2025

In this review we examine the neuroprotective potential of NAP (davunetide), a small peptide derived from Activity-Dependent Neuroprotective Protein (ADNP), in context neurodevelopmental and neurodegenerative disorders. ADNP, protein essential for brain development function, is associated with tauopathy-related diseases, such as Alzheimer's Disease (AD), circadian rhythm regulation. enhances microtubule stability prevents tauopathy. preclinical studies, shows promise improving cognitive performance correcting behavioral deficits different models. Clinical studies on (davunetide) administered via intranasal delivery have demonstrated its safety, favorable bioavailability, efficacy making it viable therapeutic option. pure tauopathy, progressive supranuclear palsy, significantly slowed disease progression women phase II-III clinical trial. Additionally, complex interactions between pathways, regulation extensive compensation upon ADNP deficiency attest to further development. Thus, an example reductionist approach drug delivery, replacing/enhancing critical large ADNP-related pathways including dysregulated microtubules tauopathy bioavailable investigational drug, davunetide.

Язык: Английский

Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer’s disease DOI Creative Commons
Xuemei Zeng,

Tara K Lafferty,

Anuradha Sehrawat

и другие.

Molecular Neurodegeneration, Год журнала: 2024, Номер 19(1)

Опубликована: Окт. 10, 2024

Blood-based biomarkers are gaining grounds for the detection of Alzheimer's disease (AD) and related disorders (ADRDs). However, two key obstacles remain: lack methods multi-analyte assessments need pathophysiological processes like neuroinflammation, vascular, synaptic dysfunction. A novel proteomic method pre-selected analytes, based on proximity extension technology, was recently introduced. Referred to as NULISAseq CNS panel, assay simultaneously measures ~ 120 analytes neurodegenerative diseases, including those linked both core (i.e., tau amyloid-beta (Aβ)) non-core AD processes. This study aimed evaluate technical clinical performance this targeted panel.

Язык: Английский

Процитировано

5
A preliminary study on plasma markers across cognitive stages and links to a history of mild traumatic brain injury DOI Creative Commons
Christian LoBue, Barbara E. Stopschinski, Nil Saez-Calveras

и другие.

Journal of Alzheimer s Disease, Год журнала: 2025, Номер unknown

Опубликована: Март 21, 2025

Potential implications of a history mild traumatic brain injury (mTBI) during aging are understudied. Seven plasma markers were measured in matched participants having normal cognition, cognitive impairment (MCI) and dementia the Alzheimer's type (DAT) with without mTBI. Phosphorylated tau 181 showed moderate effect size for being greater mTBI + individuals MCI DAT, sizes lower amyloid-β 42/40 higher neurofilament light seen DAT individuals. This preliminary report shows potential role plasma-derived detecting associations between development disease related disorders.

Язык: Английский

Процитировано

0
Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity DOI Creative Commons
Artur Galushkin, Illana Gozes

Advanced Drug Delivery Reviews, Год журнала: 2025, Номер 220, С. 115573 - 115573

Опубликована: Апрель 4, 2025

In this review we examine the neuroprotective potential of NAP (davunetide), a small peptide derived from Activity-Dependent Neuroprotective Protein (ADNP), in context neurodevelopmental and neurodegenerative disorders. ADNP, protein essential for brain development function, is associated with tauopathy-related diseases, such as Alzheimer's Disease (AD), circadian rhythm regulation. enhances microtubule stability prevents tauopathy. preclinical studies, shows promise improving cognitive performance correcting behavioral deficits different models. Clinical studies on (davunetide) administered via intranasal delivery have demonstrated its safety, favorable bioavailability, efficacy making it viable therapeutic option. pure tauopathy, progressive supranuclear palsy, significantly slowed disease progression women phase II-III clinical trial. Additionally, complex interactions between pathways, regulation extensive compensation upon ADNP deficiency attest to further development. Thus, an example reductionist approach drug delivery, replacing/enhancing critical large ADNP-related pathways including dysregulated microtubules tauopathy bioavailable investigational drug, davunetide.

Язык: Английский

Процитировано

0